Opioid maintenance: A comparative review of pharmacological strategies

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 1, 2007, Pages 1-11

  White, Jason M ^a   Lopatko, Olga V ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CYTOCHROME P450 3A4; DIAMORPHINE; DRUG METABOLITE; LEVACETYLMETHADOL; LONG ACTING DRUG; METHADONE; MORPHINE; MORPHINE 6 ACETATE; NALOXONE; NALTREXOL; NALTREXONE; OPIATE; OPIATE AGONIST; PARTIAL AGONIST; PLACEBO;

ALCOHOLISM; BONE DENSITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG SUBSTITUTION; DRUG TOLERANCE; FATIGUE; HEADACHE; HEROIN DEPENDENCE; HUMAN; INFLAMMATION; INTOXICATION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NAUSEA; OPIATE ADDICTION; PAIN; PATIENT ATTITUDE; PRESCRIPTION; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; QT PROLONGATION; RELAPSE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SLOW RELEASE FORMULATION; TABLET FORMULATION; XEROSTOMIA;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 33846117240     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.1.1     Document Type: Review

References (99)

1. NENCINI P: The rules of drug taking: wine and poppy derivatives in the Ancient World. VIII. Lack of evidence of opium addiction. Subst. Use Misuse (1997) 32(11):1581-1586.
2. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR. American Psychiatric Association, Washington, DC, (2000):xxxvii, 943.
3. HYMAN SE, MALENKA RC, NESTLER EJ: Neural mechanisms of addiction: the role of reward-related learning and memory. Ann. Rev. Neurosci. (2006) 29:565-598.
4. ANTHONY JC, WARNER LA, KESSLER RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Co-morbidity Survey. Exp. Clin. Psychopharmacol. (1994) 2:244-268.
5. COMPTON WM, VOLKOW ND: Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. (2006) 81(2):103-107.
6. COMPTON WM, VOLKOW ND: Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. (2006) 83(Suppl. 1):S4-S7.
7. BRANDS B, BLAKE J, SPROULE B, GOURLAY D, BUSTO U: Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. (2004) 73(2):199-207.
8. O'BRIEN CP: Research advances in the understanding and treatment of addiction. Am. J. Addict. (2003) 12(Suppl. 2):S36-S47.
9. HALLINAN R, RAY J, BYRNE A, AGHO K, ATTIA J: Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. Drug Alcohol Depend. (2006) 81(2):129-136.
10. KRAFT MK, ROTHBARD AB, HADLEY TR, MCLELLAN AT, ASCH DA: Are supplementary services provided during methadone maintenance really cost-effective? Am. J. Psychiatry (1997) 154(9):1214-1219.
11. GOWING LR, ALI RL: The place of detoxification in treatment of opioid dependence. Curr. Opin. Psychiatry. (2006) 19(3):266-270.
12. DOLE VP, NYSWANDER ME: Rehabilitation of heroin addicts after blockade with methadone. N. Y. State J. Med. (1966) 66(15):2011-2017.
13. CODD EE, SHANK RP, SCHUPSKY JJ, RAFFA RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J. Pharmacol. Exp. Ther. (1995) 274(3):1263-1270.
14. GORMAN AL, ELLIOTT KJ, INTURRISI CE: The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. (1997) 223(l):5-8.
15. FERRARI A, COCCIA CP, BERTOLINI A, STERNIERI E: Methadone - metabolism, pharmacokinetics and interactions. Pharmacol. Res. (2004) 50(6):551-559.
16. EAP CB, BUCLIN T, BAUMANN P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. (2002) 41(14):1153-1193.
17. DYER KR, FOSTER DJ, WHITE JM et al.: Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin. Pharmacol. Ther. (1999) 65(6):685-694.
18. TRAFTON JA, MINKEL J, HUMPHREYS K: Determining effective methadone doses for individual opioid-dependent patients. PLoS Med (2006) 3(3):e8O.
19. FAGGIANO F, VIGNA-TAGLIANTI F, VERSINO E, LEMMA P: Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. (2006) (3):CD002208.
20. STRAIN EC, STITZER ML: Methadone Treatment for Opioid Dependence. Johns Hopkins University Press, Baltimore (1999).
21. MATTICK RP, BREEN C, KIMBER J, DAVOLI M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Datahase Syst. Rev. (2006) (3):CD002209.
22. SULLIVAN LE, METZGER DS, FUDALA PJ, FIELLIN DA: Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction (2005) 100(2):150-158.
23. BARNETT PG: The cost-effectiveness of methadone maintenance as a health care intervention. Addiction (1999) 94(4):479-488.
24. FIELLIN DA, O'CONNOR PG, CHAWARSKI M et al.: Methadone maintenance in primary care: a randomized controlled trial. JAMA (2001) 286(14):1724-1731.
25. MERRILL JO, JACKSON TR, SCHULMAN BA et al.: Methadone medical maintenance in primary care. An implementation evaluation. J. Gen. Intern. Med. (2005) 20(4):344-349.
26. KORNOR H, WAAL H: From opioid maintenance to abstinence: a literature review. Drug. Alcohol. Rev. (2005) 24(3):267-274.
27. ZADOR DA, SUNJIC SD: Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug. Alcohol. Rev. (2002) 21(2):131-136.
28. EHRET GB, VOIDE C, GEX-FABRY M et al.: Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. (2006) 166(12):1280-1287.
29. LINTZERIS N, MITCHELL TB, BOND A, NESTOR L, STRANG J: Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J. Clin. Psychopharmacol. (2006) 26(3):274-283.
30. MCCANCE-KATZ EF, RAINEY PM, SMITH P et al.: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. (2006) 15(1):23-34.
31. RITTER A, DI NATALE R: The relationship between take-away methadone policies and methadone diversion. Drug. Alcohol. Rev. (2005) 24(4):347-352.
32. CORKERY JM, SCHIFANO F, GHODSE AH, OYEFESO A: The effects of methadone and its role in fatalities. Hum. Psychopharmacol. (2004) 19(8):565-576.
33. KIM TW, ALFORD DP, MALABANAN A, HOLICK MF, SAMET JH: Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. (2006) 85(3):258-262.
34. HENDERSON GL, WILSON BK, LAU DH: Plasma 1-α-acetylmethadol (LAAM) after acute and chronic administration. Clin. Pharmacol. Ther. (1977) 21(l):16-25.
35. FINKLE BS, JENNISON TA, CHINN DM, LING W, HOLMES ED: Plasma and urine disposition of I-α-acetylmethadol and its principal metabolites in man. J. Anal. Toxicol. (1982) 6(2):100-105.
36. LONGSHORE D, ANNON J, ANGLIN MD, RAWSON RA: Levo-α-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction (2005) 100(8):1131-1139.
37. CLARK N, LINTZERIS N, GIJSBERS A et al.: LAAM maintenance versus methadone maintenance for heroin dependence. Cochrane Database Syst. Rev. (2006) (3):CD002210.
38. DEAMER RL, WILSON DR, CLARK DS, PRICHARD JG: Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J. Addict. Dis. (2001) 20(4):7-14.
39. LING W, RAWSON RA, COMPTON MA: Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoactive Drugs (1994) 26(2):119-128.
40. KANG J, CHEN XL, WANG H, RAMPE D: Interactions of the narcotic l-α-acetylmethadol with human cardiac K+ channels. Eur. J. Pharmacol. (2003) 458(1-2):25-29.
41. MITCHELL TB, WHITE JM, SOMOGYI AA, BOCHNER F: Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction (2004) 99(8):940-945.
42. EDER H, JAGSCH R, KRAIGHER D et al.: Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction (2005) 100(8):1101-1109.
43. FISCHER G, JAGSCH R, EDER H et al.: Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction (1999) 94(2):231-239.
44. PATERSON S, LINTZERIS N, MITCHELL TB et al.: Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction (2005) 100(12):1832-1839.
45. ROOK EJ, HUITEMA AD, VAN DEN BRINK W, VAN REE JM, BEIJNEN JH: Population pharmacokinetics of heroin and its major metabolites. Clin. Pharmacokinet. (2006) 45(4):401-417.
46. ROSSI GC, BROWN GP, LEVENTHAL L, YANG K, PASTERNAK GW: Novel receptor mechanisms for heroin and morphine-6 β-glucuronide analgesia. Neurosci. Lett. (1996) 216(l):1-4.
47. MITCHELL TB, LINTZERIS N, BOND A, STRANG J: Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment. Eur. Addict. Res. (2006) 12(2):91-95.
48. FERRI M, DAVOLI M, PERUCCI CA: Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness. J. Subst. Abuse Treat. (2006) 30(l):63-72.
49. VAN DEN BRINK W, HENDRIKS VM, BLANKEN P et al.: Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Br. Med. J. (2003) 327(7410):310.
50. WODAK A: The current status of heroin prescription treatment for heroin dependence. Expert. Opin. Drug. Saf. (2005) 4(5):815-819.
51. DIJKGRAAF MG, VAN DER ZANDEN BP, DE BORGIE CA et al.: Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Br. Med. J. (2005) 330(7503):1297.
52. KLOUS MG, ROOK EJ, HILLEBRAND MJ et al.: Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program. J. Anal. Toxicol. (2005) 29(6):564-569.
53. DAHAN A: Opioid-induced respiratory effects: new data on buprenorphine. Palliat. Med. (2006) 20(Suppl. 1):s3-s8.
54. HUANG P, KEHNER GB, COWAN A, LIU-CHEN LY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. (2001) 297(2):688-695.
55. MARQUET P: Pharmacology of high dose buprenorphine. In Buprenorphine Therapy of Opiate Addiction. Kintz P et al. (eds) Humana Press, Totowa (NJ) (2002): 1-11.
56. MEGARBANE B, MARIE N, PIRNAY S et al.: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. (2006) 212(3):256-267.
57. ELKADER A, SPROULE B: Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. (2005) 44(7):661-680.
58. FISHMAN J, ROFFWARG H, HELLMAN L: Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. J. Pharmacol. Exp. Ther. (1973) 187(3):575-580.
59. STOLLER KB, BIGELOW GE, WALSH SL, STRAIN EC: Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (2001) 154(3):230-242.
60. MENDELSON J, JONES RT: Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. (2003) 70(2S):S29-S37.
61. PETRY NM, BICKEL WK, BADGER GJ: A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction (2000) 95(7):1069-1077.
62. EISSENBERG T, JOHNSON RE, BIGELOW GE et al.: Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcobol Depend. (1997) 45(1-2):81-91.
63. AMASS L, BICKEL WK, CREAN JP, BLAKE J, HIGGINS ST: Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (1998) 136(3):217-225.
64. BREEN CL, HARRIS SJ, LINTZERIS N et al.: Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. (2003) 71(1):49-55.
65. LING W, WESSON DR: Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. (2003) 70(2 Suppl.):S49-S57.
66. MATTICK RP, KIMBER J, BREEN C, DAVOLI M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. (2006) (3):
67. FUDALA PJ, BRIDGE TP: Foreword to: buprenorphine and buprenorphine/ naloxone: a guide for clinicians. Drug Alcobol Depend. (2003) 70(2 Suppl.):S1-S2.
68. COMER SD, COLLINS ED: Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. (2002) 303(2):695-703.
69. STRAIN EC, STOLLER K, WALSH SL, BIGELOW GE: Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopbarmacology (2000) 148(4):374-383.
70. GONZALEZ JP, BROGDEN RN: Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs (1988) 35(3):192-213.
71. RESNICK RB, VOLAVKA J, FREEDMAN AM, THOMAS M: Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am. J. Psychiatry (1974) 131(6):646-650.
72. VEREBEY K, VOLAVKA J, MULE SJ, RESNICK RB: Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pbarmacol. Ther. (1976) 20(3):315-328.
73. MEYER MC, STRAUGHN AB, LO MW, SCHARY WL, WHITNEY CC: Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry (1984) 45(9 Pt 2):15-19.
74. VOLPICELLI JR, FENTON M: Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol. (2006) 1(4):389-398.
75. PORTER SJ, SOMOGYI AA, WHITE JM: Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol. (2000) 50(5):465-471.
76. JOHNSON BA: A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin. Pharmacother. (2006) 7(8):1065-1073.
77. GALLOWAY GP, KOCH M, CELLO R, SMITH DE: Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry (2005) 5(1):18.
78. FOSTER J, BREWER C, STEELE T: Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict. Biol. (2003) 8(2):211-217.
79. HULSE GK, ARNOLD-REED DE, O'NEIL G et al.: Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict. Biol. (2004) 9(1):59-65.
80. WAAL H, FROGOPSAHL G, OLSEN L, CHRISTOPHERSEN AS, MORLAND J: Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study. Eur. Addict. Res. (2006) 12(3):138-144.
81. KIRCHMAYER U, DAVOLI M, VERSTER AD et al.: A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction (2002) 97(10):1241-1249.
82. MINOZZI S, AMATO L, VECCHI S et al.: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. (2006) (1):CD001333.
83. ROOZEN HG, DE WAART R, VAN DER WINDT DA et al.: A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur. Neuropsychopharmacol. (2006) 16(5):311-323.
84. JOHANSSON BA, BERGLUND M, LINDGREN A: Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction (2006) 101(4):491-503.
85. TUCKER TK, RITTER A: Naltrexone in the treatment of heroin dependence: a literature review. Drug. Alcohol Rev. (2000) 19:73-82.
86. REA F, BELL JR, YOUNG MR, MATTICK RP: A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend. (2004) 75(1):79-88.
87. KRUPITSKY EM, ZVARTAU FE, MASALOV DV et al.: Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J. Subst. Abuse Treat. (2004) 26(4):285-294.
88. COMER SD, SULLIVAN MA, YU F. et al.: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry (2006) 63(2):210-218.
89. CARRENO JE, ALVAREZ CE, NARCISO GI et al.: Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict. Biol. (2003) 8(4):429-438.
90. OLSEN L, CHRISTOPHERSEN AS, FROGOPSAHL G, WAAL H, MORLAND J: Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br. J. Clin. Pharmacol. (2004) 58(2):219-222.
91. TUCKER TK, RITTER A, MAHER C, JACKSON H: Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug. Alcohol. Rev. (2004) 23(3):299-309.
92. WHITE JM, IRVINE RJ: Mechanisms of fatal opioid overdose. Addiction (1999) 94(7):961-972.
93. DIGIUSTO E, SHAKESHAFT A, RITTER A, O'BRIEN S, MATTICK RP: Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction (2004) 99(4):450-460.
94. JOHNSON RE, CHUTUAPE MA, STRAIN EC et al.: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. (2000) 343(18):1290-1297.
95. KLEPPNER SR, PATEL R, MCDONOUGH J, COSTANTINI LC: In-vitro and in-vivo characterization of a buprenorphine delivery system. J. Pharm. Pharmacol. (2006) 58(3):295-302.
96. SIGMON SC, WONG CJ, CHAUSMER AL, LIEBSON IA, BIGELOW GE: Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction (2004) 99(11):1439-1449.
97. SOBEL BF, SIGMON SC, WALSH SL et al.: Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. (2004) 73(1):11-22.
98. POLLACK MH, PENAVA SA, BOLTON E et at: A novel cognitive-behavioral approach for treatment-resistant drug dependence. J Subst. Abuse Treat. (2002) 23(4):335-342.
99. DOVERTY M, WHITE JM, SOMOGYI AA et al.: Hyperalgesic responses in methadone maintenance patients. Pain (2001) 90(1-2):91-96.